These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 23558218)

  • 21. Recognition and treatment of anemia in the setting of heart failure due to systolic left ventricular dysfunction.
    Howlett JG
    Expert Rev Cardiovasc Ther; 2008 Feb; 6(2):199-208. PubMed ID: 18248274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anemia in chronic heart failure: should we treat it and how?
    Komajda M
    J Am Coll Cardiol; 2007 Feb; 49(7):763-4. PubMed ID: 17306704
    [No Abstract]   [Full Text] [Related]  

  • 23. Further aspects of anemia, heart failure, and erythropoietin.
    Kovacic JC
    J Am Coll Cardiol; 2005 May; 45(9):1549-50; author reply 1550-1. PubMed ID: 15862435
    [No Abstract]   [Full Text] [Related]  

  • 24. Darbepoetin alfa in anemia of myelodysplastic syndromes: present and beyond.
    Kelaidi C; Fenaux P
    Expert Opin Biol Ther; 2010 Apr; 10(4):605-14. PubMed ID: 20201708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of anaemia in chronic heart failure--optimal approach still unclear.
    Murphy NF; McDonald K
    Eur Heart J; 2007 Sep; 28(18):2185-7. PubMed ID: 17704094
    [No Abstract]   [Full Text] [Related]  

  • 26. Beta-erythropoietin effects on ventricular remodeling, left and right systolic function, pulmonary pressure, and hospitalizations in patients affected with heart failure and anemia.
    Palazzuoli A; Silverberg DS; Calabrò A; Spinelli T; Quatrini I; Campagna MS; Franci B; Nuti R
    J Cardiovasc Pharmacol; 2009 Jun; 53(6):462-7. PubMed ID: 19455052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epoetin alfa and darbepoetin alfa go head to head.
    Steensma DP; Loprinzi CL
    J Clin Oncol; 2006 May; 24(15):2233-6. PubMed ID: 16710021
    [No Abstract]   [Full Text] [Related]  

  • 28. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial.
    McMurray JJ; Anand IS; Diaz R; Maggioni AP; O'Connor C; Pfeffer MA; Polu KR; Solomon SD; Sun Y; Swedberg K; Tendera M; van Veldhuisen DJ; Wasserman SM; Young JB;
    Eur J Heart Fail; 2009 Aug; 11(8):795-801. PubMed ID: 19633103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anemia in heart failure: an overview of current concepts.
    von Haehling S; Jankowska EA; Ponikowski P; Anker SD
    Future Cardiol; 2011 Jan; 7(1):119-29. PubMed ID: 21174515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future directions in management of anemia in heart failure.
    Agarwal AK; Katz SD
    Heart Fail Clin; 2010 Jul; 6(3):385-95. PubMed ID: 20630412
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiorenal anemia syndrome: do erythropoietin and iron therapy have a place in the treatment of heart failure?
    Pagourelias ED; Koumaras C; Kakafika AI; Tziomalos K; Zorou PG; Athyros VG; Karagiannis A
    Angiology; 2009; 60(1):74-81. PubMed ID: 18413330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comment: Epoetin alfa versus darbepoetin alfa for cancer patients with treatment-related anemia.
    Yang MC
    Ann Pharmacother; 2006 May; 40(5):998-9; author reply 999. PubMed ID: 16670351
    [No Abstract]   [Full Text] [Related]  

  • 33. [Comorbidity: anemia and heart failure].
    Mahfoud F; Kindermann I; Kindermann M; Ukena C; Böhm M
    Dtsch Med Wochenschr; 2009 Apr; 134(16):825-30. PubMed ID: 19353467
    [No Abstract]   [Full Text] [Related]  

  • 34. [Erythropoiesis-stimulating agents in congestive heart failure patients].
    Robles Perez-Monteoliva NR; Macías Núñez JF; Herrera Pérez de Villar J
    Med Clin (Barc); 2014 Mar; 142(5):215-8. PubMed ID: 24012446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The American Heart Association's Scientific Sessions 2006. Chicago, IL, November 12-15, 2006.
    von Haehling S
    Heart Fail Monit; 2007; 5(3):101-3. PubMed ID: 17487298
    [No Abstract]   [Full Text] [Related]  

  • 36. Epoetins and [symbol: see text] darbepoetin alfa in malignant disease.
    Drug Ther Bull; 2004 Mar; 42(3):21-3. PubMed ID: 15038080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A meta-analysis of erythropoiesis-stimulating agents in anaemic patients with chronic heart failure.
    Jin B; Luo X; Lin H; Li J; Shi H
    Eur J Heart Fail; 2010 Mar; 12(3):249-53. PubMed ID: 20031949
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Would prescription of erythropoiesis-stimulating agents in pre-dialysis change after results from TREAT study?].
    Alcázar R; Tato A; García F; Barrios V; Quereda C
    Nefrologia; 2010; 30(1):114-8. PubMed ID: 20038963
    [No Abstract]   [Full Text] [Related]  

  • 39. Erythropoietins should be used according to guidelines.
    Aapro MS; Birgegård G; Bokemeyer C; Cornes P; Foubert J; Gascon P; Glaspy J; Hellström-Lindberg E; Link H; Ludwig H; Osterborg A; Repetto L; Soubeyran P
    Lancet Oncol; 2008 May; 9(5):412-3. PubMed ID: 18452853
    [No Abstract]   [Full Text] [Related]  

  • 40. Does TREAT give the boot to ESAs in the treatment of CKD anemia?
    Singh AK
    J Am Soc Nephrol; 2010 Jan; 21(1):2-6. PubMed ID: 20035034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.